Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced its participation in two upcoming investor conferences in New York, NY:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, at 4:50 p.m. Eastern Time
• Baird 2024 Global Healthcare Conference on September 11, 2024, at 9:40 a.m. Eastern Time

Both events will feature fireside chats, which will be livestreamed on Acadia's website and archived for approximately one month. Acadia, a neuroscience-focused company, has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their ongoing clinical research targets Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:

Morgan Stanley 22^nd Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY

Baird 2024 Global Healthcare Conference
Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern Time in New York, NY

Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826097160/en/

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When is Acadia Pharmaceuticals (ACAD) participating in the Morgan Stanley Global Healthcare Conference?

Acadia Pharmaceuticals (ACAD) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 4:50 p.m. Eastern Time in New York, NY.

What is the date and time of Acadia's (ACAD) fireside chat at the Baird Global Healthcare Conference?

Acadia Pharmaceuticals (ACAD) will have a fireside chat at the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024, at 9:40 a.m. Eastern Time in New York, NY.

How can investors access Acadia's (ACAD) presentations at the upcoming conferences?

Investors can access live webcasts of Acadia's (ACAD) fireside chats at both conferences on the company's website, Acadia.com, under the investors section. Archived recordings will be available for approximately one month following each presentation.

What are the main therapeutic areas Acadia Pharmaceuticals (ACAD) focuses on?

Acadia Pharmaceuticals (ACAD) focuses on neuroscience, with FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage research targets Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in central nervous system disorders.